Tim Smith

These findings, to be presented at AAAAI, highlight the importance of labeling different cleansing products used by consumers with eczema.

Additional research may be necessary to look at the sequence of epinephrine administration and advanced airway management in settings in which alternative epinephrine administration strategies are utilized.

Additional validation of such improvement thresholds using unblinded trial data may be necessary to allow for more evidence of their utility in clinical research and practice.

In this Lungcast segment, Spicer spoke on several treatment-specific biomarkers for lung cancer and discussed the future of lung cancer therapy.

During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.

In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.

Additional research on this form of moisturizer and other ingredients for acne with larger sample sizes may be needed to verify efficacy for acne vulgaris.

This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.

This segment of Lungcast features a discussion with Spicer about the timing of lung cancer treatment, as well as evolution of adjuvant and neoadjuvant therapies.

In addition to the newly-accepted BLA in the US, the European Medicines Agency also accepted the drug’s Marketing Authorization Application for both conditions.

For patients with chronic rhinosinusitis, seasonal allergies may only make the condition feel worse for patients, though the relationship is still poorly defined.

The findings in a recent phase 3 clinical study may allow Kalvista Pharma to seek FDA approval for this potential hereditary angioedema treatment option.

These data may allow for future research into the ways in which adolescent patients may better control their allergic condition.

This review and meta-analysis yielded results which confirmed prior data on maternal asthma and neonatal outcomes, in addition to establishing several new findings.

These findings on reasons for attendance and other trends highlight the importance of mental health care among alopecia patients.

These data were found to be consistent with the findings in the main study, the contents of which suggested the treatments’ interchangeability.

In this interview, Palmer shares several of the key findings and their implications for the future of this patient population.

These new data highlight the efficacy of JNJ-77242113 as a potential oral therapy option for moderate-to-severe psoriasis patients.

The FDA set its target action date for October, with this sNDA being supported by two phase 1 safety studies on AK patients.

This cohort study’s findings highlight the value of a smoking status assessment at the time of melanoma diagnoses.

These data indicate that in the US, the outpatient management of patients with pulmonary embolism identified as lower-risk may continue to be underutilized.

This analysis of trends in e-cigarette prevalence highlights several important trends among smokers, updating the current literature with new information about demographics and other data.

In new guidelines by the AAD, 18 new evidence-based recommendations and 5 practice statements were described for patients 9 years of age and older with acne.

This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

January’s Dermatology Month in Review features 2 major FDA decisions, positive results on a new assessment tool, an evaluation of climate change’s impact on eczema, and more.

This new warning for consumers cautions against use of Rebright, South Moon, or FivFivGo eye drops as a result of potential eye infection risks.

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.